Saudi Arabia Drug Registration Statistics (October 2026): What the SFDA Register Shows

FreeScore your brand plan before management does. Send me the scorecard

Most market reports about Saudi pharma quote a market value and a growth rate, and stop there. Brand and launch teams need something more concrete: how crowded is my category, who else is registered in it, how fast are new competitors arriving, and where do OTC products actually sit. The Saudi Food and Drug Authority publishes the answer in its drug register, but the register is a list of thousands of entries, not a report. This page counts it.

Every figure below is read from the SFDA's own open-data register, all 14,145 entries, and recounted every month. Each number carries its date. If you quote one, quote the date with it.

How many medicines are registered in Saudi Arabia?

9,207 medicines have a valid SFDA registration as of 23 October 2026, out of 14,145 entries in the register. They cover 1,816 distinct scientific names (active ingredients or combinations) and come from 693 companies.

The other entries tell their own story. 4,140 were withdrawn by the marketing authorization holder, that is by the company itself, 303 were withdrawn by the regulator and 171 are suspended. In other words, for every two products still valid there is almost one that a company registered and later gave up. That is the hidden cost of a registration strategy built on volume: dossiers are expensive to file and to maintain, and a large share do not survive.

What share of registered medicines in Saudi Arabia are OTC?

7.6% of valid registrations are OTC: 697 products, against 8,510 prescription-only products. That is a small OTC register for a market where the pharmacy counter carries so much of consumer healthcare. Much of what a Saudi shopper buys without a prescription (vitamins, supplements, skin care, oral care) is not registered as a medicine at all but under the SFDA's food, cosmetics or health-product rules, so it does not appear here.

For an OTC brand team this has two consequences. First, the true competitive set on the shelf is wider than the OTC register: a cough syrup competes with registered OTC syrups, but also with herbal and supplement products filed under other rules. Second, an OTC medicine registration is itself a differentiator. It is the one claim a supplement cannot make, and the positioning should use it. Our guide to pharma brand positioning shows how to turn a regulatory fact like this into a reason to believe.

Are most Saudi registrations generics or new medicines?

Generics dominate: 6,252 valid registrations (67.9%), against 2,036 new chemical entities (22.1%) and 904 biologicals (9.8%).

The ratio of roughly two generics for every innovative product matters for anyone planning a launch. Michael Porter's five forces (Porter, 1979) put rivalry among existing competitors and the threat of substitutes at the centre of an industry's profitability. In a molecule that already has several registered generics, rivalry is high and price is the easiest weapon. The register lets a team count those rivals before writing a business case, molecule by molecule, rather than guessing. Our OTC launch playbook walks through that check.

Which therapy areas have the most registered medicines?

Nervous system leads with 1,334 valid registrations (14.5%). The six largest therapy areas are close together, each with roughly a tenth or more of the register; together they account for most of it.

Two readings help here. The first is crowding: a therapy area with many registrations is not automatically a large market, but it is a busy one, and a new entrant there needs a sharper point of difference. The second is mix: the strong showing of antineoplastic and immunomodulating agents reflects the specialty and hospital side of the market, where the buyer is a formulary committee, not a shopper. Marketing those products is a different discipline, closer to the work described in our guide to HCP engagement.

Which therapy areas lead the OTC register?

Respiratory system products lead the OTC register with 194 of 697 (27.8%), followed by alimentary tract and metabolism with 156 (22.4%).

The OTC register looks nothing like the prescription one. Respiratory products (cough, cold, nasal and throat) and alimentary products (antacids, laxatives, vitamins registered as medicines) make up the core; cardiovascular and oncology barely appear. This is the classic self-care basket: short, recognisable episodes that a shopper is confident to treat without a doctor.

Byron Sharp's work on how brands grow (Sharp, 2010) argues that in categories like these, growth comes mainly from mental and physical availability: being the brand that comes to mind when the cough starts, and being on the shelf where the shopper looks. Because the OTC register is concentrated in a handful of need-states, the brands that win are usually the ones present in all of them at the moment of need, not the ones with the cleverest claim. For the shelf side of that, see our guide to pharmacy merchandising strategy.

How many new medicines does the SFDA register each year?

840 of today's valid registrations carry the register year 2026, up to 23 October 2026, already more than the 759 from 2025. 5,984 valid registrations, 65.0% of the register, date from 2016 or later.

Read this chart with its limit in mind: it counts products registered in each year that are still valid today. The early years look small partly because their withdrawals have been removed. Even so, the recent run is clear. The register has been adding several hundred surviving products a year since 2016, and 2026 is on course to be the busiest year in the data.

On the OTC side the same pattern shows at a smaller scale: 46 valid OTC registrations carry the year 2026 so far, against 22 in 2025.

Everett Rogers' diffusion of innovations (Rogers, 1962) describes how adoption spreads through a population in stages. A faster registration pipeline speeds up the supply side of that curve: more options reach the shelf and the formulary sooner, and the window in which a first entrant enjoys the market alone gets shorter. For a launch plan this means the competitive review cannot be a one-off; it needs a check of new registrations every month until launch. Our launch plan and readiness workbook builds that check into the plan.

Which companies hold the most registrations in Saudi Arabia?

Jazeera Pharmaceutical Industries (JPI) holds the most valid registrations (482), and the top five companies together hold 20.4% of the register. The fifteen largest hold 37.1%; the remaining registrations are spread across hundreds of companies.

The list is led by local and regional manufacturers with large generic portfolios, which fits the generic share above and the policy push to manufacture more medicines inside the Kingdom. Note what the table does not say: a registration count is not a sales ranking. A multinational with a few large brands can sell far more than a company with hundreds of registered strengths. The count measures breadth of portfolio, not share of market.

The OTC register has a different leader board:

Company names appear exactly as the SFDA records them, with spacing cleaned so that one company is not counted twice. Some groups register under several legal entities; this page does not merge them.

What do OTC and prescription medicines cost in Saudi Arabia?

The median public price of a valid OTC pack is SAR 14.35; the median prescription pack lists at SAR 87.70, about 6.1 times as much.

These are register list prices per pack, so they say nothing about volume or discounting. They are still useful as anchors. A new OTC product priced far above the median needs a reason the shopper can see on the pack; one priced far below it may leave the pharmacy too little margin to recommend it. Our pharmacy trade margin calculator shows what a given public price leaves for the pharmacy and the distributor, and the OTC launch budget estimator turns a price into a first-year plan.

What dosage forms dominate the OTC register?

Tablets lead: tablet (116) and film-coated tablet (94), followed by syrup (92).

The strong place of syrups reflects the size of the respiratory OTC basket and of children's medicines. Creams and gels follow the dermatological and musculo-skeletal products. Form is a quiet positioning lever: in a crowded tablet segment, a chewable, a liquid or a topical form can be the difference a shopper notices, provided it solves a real problem (a child who will not swallow a tablet, a pain the shopper wants to treat where it hurts).

What does this mean for brand and launch teams?

Five practical readings, each tied to a decision a brand team makes.

1. Count your rivals before you write the business case. The register lets you list every valid product on your molecule and form. If there are already many generics, plan for price competition from the start; Porter's rivalry force is visible in the data.
2. Use the OTC status as a claim. With only 7.6% of medicines registered OTC and much of self-care sold under other rules, being a registered medicine is a reason to believe that a supplement cannot copy.
3. Plan for availability, not just persuasion. The OTC register is concentrated in a few need-states. Following Sharp (2010), the job is to be present and easy to find in each of them, from shelf to search.
4. Watch the pipeline monthly. With 2026 already the busiest year in the data, a competitor review done once at the start of a launch project will be out of date by launch day.
5. Anchor your price. The median OTC and prescription list prices give a reference point for the price-value story you will need to defend with the pharmacy and the shopper.

Kotler and Keller (Marketing Management, 15th ed., 2016) define the start of every marketing plan as a disciplined look at the market as it is. Most teams in the region do this with expensive panel data or not at all. The register is free, official and complete for registered medicines; it should be the first page of every Saudi brand plan. The in-licensing and BD evaluation workbook and the brand plan template both have a place for it, and our pharma marketing strategy guide shows where it fits in the wider plan.

How do I use the SFDA register in a brand plan?

1. List every valid product on your molecule, combination or category, with its company, form, strength and price.
2. Mark which are OTC and which need a prescription, and which are generic or innovative.
3. Note the register year of each, to see how recently competitors arrived.
4. Plot their public prices against yours, per pack and per daily dose.
5. Repeat the check monthly from the business case until six months after launch.

For the regulatory side of what you may say about the product once it is registered, our guide to SFDA marketing compliance covers the rules for claims, promotion and social media.

How should I cite these statistics?

Sources

• Saudi Food and Drug Authority, Registered Drug service, open-data developer portal (developer.sfda.gov.sa), read 23 October 2026.
• WHO Collaborating Centre for Drug Statistics Methodology, ATC classification system, level-1 anatomical main groups.
• Porter, M. E. (1979). How competitive forces shape strategy. Harvard Business Review.
• Sharp, B. (2010). How Brands Grow. Oxford University Press.
• Rogers, E. M. (1962). Diffusion of Innovations. Free Press.
• Kotler, P. and Keller, K. L. (2016). Marketing Management, 15th edition. Pearson.